This Form 10-K/A amends the original 2025 Annual Report to include mandatory Part III disclosures. The filing provides detailed information on the board of directors, executive compensation, and related party transactions. No changes were made to previously reported financial results. The company confirmed its pending acquisition by Gilead Sciences, Inc. for $115.00 per share plus a contingent value right (CVR) of $5.00. The board consists of eight directors, seven of whom are independent.